The VIEW-hub report displays data and figures on the introduction, use, and coverage status of typhoid conjugate, human papillomavirus, pneumococcal, rotavirus, Haemophilus influenzae type b, and inactivated polio vaccines both globally and in the

This document outlines the methods used in the COVID-19 vaccine safety literature review presented in the VIEW-hub COVID safety studies module.

In partnership with the Asian Development Bank, IVAC summarized the evidence for COVID-19 vaccine performance against Omicron sub-variants.

This document provides an overview of the available laboratory evidence on the ability of the bivalent Omicron-containing mRNA COVID-19 vaccines to neutralize Omicron subvariants.

These forest plots summarize the available evidence on the vaccine effectiveness of the bivalent Omicron-containing mRNA COVID-19 vaccines.

In partnership with the Asian Development Bank, IVAC developed factsheets summarizing key measures for COVID-19 vaccines such as effectiveness and protection against severe disease.

In partnership with the Asian Development Bank, IVAC developed factsheets summarizing key measures for COVID-19 vaccines such as effectiveness and protection against severe disease.

In partnership with the Asian Development Bank, IVAC summarized the landscape, benefits, and challenges of next generation COVID-19 vaccines.

The VIEW-hub report displays data and figures on the introduction, use, and coverage status of typhoid conjugate, human papillomavirus, pneumococcal, rotavirus, Haemophilus influenzae type b, and inactivated polio vaccines both globally and in the

This table shows the serotypes covered by the current pneumococcal conjugate vaccine products and the three additional products that are in the development pipeline.